Amandla MK Trust Amends NRC Stake, Patrick Beans Advises

Ticker: NRC · Form: SC 13D/A · Filed: Jan 4, 2024 · CIK: 70487

National Research CORP SC 13D/A Filing Summary
FieldDetail
CompanyNational Research CORP (NRC)
Form TypeSC 13D/A
Filed DateJan 4, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$42.1037, $42.10, $42.115, $42.05, $42.0766
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: insider-ownership, amendment, institutional-investor

TL;DR

**Amandla MK Trust just updated their NRC stake, keep an eye on their next moves!**

AI Summary

The Amandla MK Trust, advised by Patrick E. Beans, filed an Amendment No. 8 to their Schedule 13D on January 2, 2024, regarding their ownership in National Research Corporation (NRC). This filing updates their beneficial ownership, indicating a change in their holdings or intentions. For investors, this matters because significant shareholders like Amandla MK Trust can influence company decisions, and changes in their filings can signal shifts in their outlook on the stock, potentially impacting its future performance.

Why It Matters

This filing updates the public on the Amandla MK Trust's position in National Research Corporation, which could signal changes in their investment strategy or influence over the company.

Risk Assessment

Risk Level: low — This is an amendment to a Schedule 13D, indicating an update to existing ownership rather than a new, potentially disruptive event.

Analyst Insight

Investors should monitor future filings from Amandla MK Trust for National Research Corporation to understand any further changes in their ownership or stated intentions, as these could influence the stock's trajectory.

Key Players & Entities

FAQ

Who is the filing person for this SC 13D/A?

The filing person for this SC 13D/A is the Amandla MK Trust, with Patrick E. Beans listed as the Special Holdings Direction Adviser and contact person.

What is the subject company of this filing?

The subject company of this filing is National Research Corporation, identified by the CUSIP Number 637372202 and the title of class of securities as Common Stock, $.001 par value.

What type of filing is this and what amendment number is it?

This is an SC 13D/A filing, which is an amendment to a Schedule 13D, and it is Amendment No. 8.

When was the event that required this filing?

The date of the event which required the filing of this statement was January 2, 2024.

What is the business address of the subject company, National Research Corporation?

The business address of National Research Corporation is 1245 Q Street, Lincoln, NE 68508.

Filing Stats: 1,177 words · 5 min read · ~4 pages · Grade level 6.8 · Accepted 2024-01-04 17:05:08

Key Financial Figures

Filing Documents

of the Schedule 13D is hereby amended and supplemented by adding the following information

Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following information: (a) Set forth below is the aggregate number and percentage of outstanding shares of Common Stock owned beneficially by each Reporting Person named in Item 2 (based on 24,558,330 shares of Common Stock outstanding as of November 3, 2023): Name Shares of Common Stock Beneficially Owned Percentage of Shares of Common Stock Beneficially Owned Trust and Adviser Common Stock –4,762,531 19.4% The Adviser is the Special Holdings Direction Adviser under the Trust and may be deemed to have sole voting and dispositive power with regard to the shares of Common Stock held by the Trust. The shares beneficially owned by the Trust are held directly by Amandla II LLC, which is 100% owned by the Trust, and Amandla LLC, which is 100% owned by Amandla II LLC. (c) The following transactions in the Common Stock have occurred during the past 60 days by the Reporting Persons: Name Trade Date Number of Shares Sold Weighted Average Price Per Share Where and How Transaction was Effected Range of Prices per Share Trust and Adviser 11/15/2023 403 $42.1037 Open market sale $42.10 to $42.115 Trust and Adviser 11/20/2023 57 $42.10 Open market sale $42.10 Trust and Adviser 11/21/2023 100 $42.05 Open market sale $42.05 Trust and Adviser 11/22/2023 627 $42.0766 Open market sale $42.05 to $42.20 Trust and Adviser 12/04/2023 100 $41.60 Open market sale $41.60 Trust and Adviser 12/05/2023 1,498 $41.60 Open market sale $41.60 Trust and Adviser 12/06/2023 952 $41.60 Open market sale $41.60 Trust and Adviser 12/07/2023 4,738 $41.5641 Open market sale $41.55 to $41.58 Trust and Adviser 12/08/2023 12,328 $41.55 Open market sale $41.55 Trust and Adviser 12/11/2023 37,638 $41.5550 Open market sale $41.55 to $41.61 Trust and Adviser 12/12/2023 21,884 $41.5501 Open market sale $41.55 to $41.56 Trust and Adviser 12/13/2023 3,779 $4

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on Read The Filing